在血友病中降低抗血素:仔细研究fitusiran
Guy Young1, Peter J Lenting2, Stacy E Croteau3
1Hemostasis and Thrombosis Center, Cancer and Blood Diseases Institute, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Research and practice in thrombosis and haemostasis
|June 26, 2023
概括
使用试验性RNA治疗药物菲图西兰降低抗血素 (AT) 水平,可以改善血友病患者的血静. 这种方法旨在重新平衡凝血系统,提高生活质量和减少治疗负担.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 凝血素是血液静止的核心,其生成受到前凝和抗凝因素的严格调节.
- 抗血 (AT) 是一种重要的天然抗凝剂,可以抑制血生成.
- 血静失衡是血友病等出血障碍的基础,需要治疗策略来恢复平衡.
研究的目的:
- 审查在血友病管理中降低AT水平的理由.
- 讨论菲图西兰的作用机制,一种针对AT的RNA治疗药物.
- 评估fitusiran作为对血友病A或B的预防性治疗的潜力.
主要方法:
- 对有关血栓生成,AT功能和血友病治疗的现有文献的综述.
- 对fitusiran作为小干扰RNA (siRNA) 治疗的机制的分析.
- 对正在进行的FITUSIRANIII期临床试验数据的审查.
主要成果:
- 菲图西兰有效地准并降低AT水平.
- 降低AT会增加血栓生成,从而增强血静.
- 临床试验表明,在血友病患者中,改善生活质量和减少治疗负担的潜力.
结论:
- 降低AT水平是重新平衡血友病中的血静的可行策略.
- 菲图西兰显示出作为一种新型预防性治疗血友病A和B的治疗方法的前景.
- 这种方法可以显著改善临床结果和患者的福祉.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
Venous Thrombosis III: Interprofessional Care
11
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
11
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K
Therapeutic Index
4.4K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
567
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
567


